IL6 and fatty liver disease: In agreement, previous studies have reported the exacerbation of steatosis by blocking IL-6 signaling in mice (Yamaguchi et al., 2010), whereas the administration of IL-6 alleviated hepatic steatosis, in part from an increase in mitochondrial β-oxidation of fatty acids (El-Assal et al., 2004; Hong et al., 2004).